National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedEstenson L, Kim N, Jacobson M
Do age-based discontinuation recommendations influence cervical cancer screening rates? Evidence from the United States' Behavioral Risk Factor Surveillance System, 2016 and 2018.
The purpose of this study was to determine how the United States Preventive Services Task Force (USPSTF) recommendation of discontinuing routine cervical cancer screening for certain women after age 65 affects Papanicolaou (Pap) test rates among women at age 66 in the United States. The researchers utilized nationally representative 2016 and 2018 Behavioral Risk Factor Surveillance System (BRFSS) data for 226,031 women ages 56-76 to calculate changes in annual Pap test rates at age 66. Among women 66-76, 22.5% indicated they had received a Pap test within the past year. At age 66, annual Pap rates decreased by 5.9 percentage points (p.p.) off a pre-66 rate of 39 percent. The change differed by race/ethnicity, education, and marital status. Pap rates did not change discretely for non-Hispanic Black women but did change for women from other racial/ethnic groups. The decrease was larger for women who graduated college than for women without a college degree and for women who were never married than for women who were married/partnered or divorced/separated. The USPSTF recommendation to stop cervical cancer screening after the age of 65 resulted in a substantial decrease in the rate of Pap tests at age 66 but disparately affects women based on marital status, education and race.
AHRQ-funded; HS026488.
Citation: Estenson L, Kim N, Jacobson M .
Do age-based discontinuation recommendations influence cervical cancer screening rates? Evidence from the United States' Behavioral Risk Factor Surveillance System, 2016 and 2018.
Prev Med 2023 Jul; 172:107543. doi: 10.1016/j.ypmed.2023.107543..
Keywords: U.S. Preventive Services Task Force (USPSTF), Cancer: Cervical Cancer, Cancer, Screening, Prevention, Evidence-Based Practice, Women, Sexual Health
Ngo-Metzger Q, Adsul P
AHRQ Author: Ngo-Metzger Q
Screening for cervical cancer.
This case study describes a 48-year-old woman, non-smoker, who has no history of sexually transmitted diseases or other remarkable conditions in her medical history. She had a human papillomavirus (HPV) test and a Pap smear three years ago, the results of both negative. The woman’s 19-year-old daughter has recently become sexually active and the woman wonders if she should schedule a Pap smear for her daughter. The case study questions are based on USPSTF recommendations for cervical cancer screening and the updated evidence report and systematic review on screening for cervical cancer with high-risk human papillomavirus testing.
AHRQ-authored.
Citation: Ngo-Metzger Q, Adsul P .
Screening for cervical cancer.
Am Fam Physician 2019 Feb 15;99(4):253-54.
.
.
Keywords: Cancer: Cervical Cancer, Case Study, Prevention, Screening, U.S. Preventive Services Task Force (USPSTF)
Kim JJ, Burger EA, Regan C
Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force.
The purpose of this study was to inform the US Preventive Services Task Force by modeling the benefits and harms of various cervical cancer screening strategies. In this microsimulation modeling study, it was estimated that primary hrHPV screening may represent a reasonable balance of harms and benefits when performed every 5 years. Switching from cytology to hrHPV testing at age 30 years yielded the most efficient harm to benefit ratio when using colposcopy as a proxy for harms.
AHRQ-funded; 290-2012-00015-I.
Citation: Kim JJ, Burger EA, Regan C .
Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force.
JAMA 2018 Aug 21;320(7):706-14. doi: 10.1001/jama.2017.19872..
Keywords: Cancer: Cervical Cancer, Shared Decision Making, Primary Care, Screening, U.S. Preventive Services Task Force (USPSTF)
Melnikow J, Henderson JT, Burda BU J, Henderson JT, Burda BU
Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force.
Cervical cancer can be prevented with detection and treatment of precancerous cell changes caused primarily by high-risk types of human papillomavirus (hrHPV), the causative agents in more than 90% of cervical cancers. The objective of this study was to systematically review benefits and harms of cervical cancer screening for hrHPV to inform the US Preventive Services Task Force.
AHRQ-funded; 290201200015I.
Citation: Melnikow J, Henderson JT, Burda BU J, Henderson JT, Burda BU .
Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2018 Aug 21;320(7):687-705. doi: 10.1001/jama.2018.10400..
Keywords: Cancer: Cervical Cancer, Evidence-Based Practice, Infectious Diseases, Screening, U.S. Preventive Services Task Force (USPSTF)